HY-P99670-1mg
|
MedChemexpress LLC
|
Iscalimab [CAS 2031153-61-2]
|
|
Metabolism-protein/nucleotide metabolism
|
|
HY-P99670-10mg
|
MedChemexpress LLC
|
Iscalimab [CAS 2031153-61-2]
|
|
Metabolism-protein/nucleotide metabolism
|
|
HY-P99670-5mg
|
MedChemexpress LLC
|
Iscalimab [CAS 2031153-61-2]
|
|
Metabolism-protein/nucleotide metabolism
|
|
HY-P99110-1mg
|
MedChemexpress LLC
|
Lanadelumab [CAS 1426055-14-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99110-10mg
|
MedChemexpress LLC
|
Lanadelumab [CAS 1426055-14-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99110-5mg
|
MedChemexpress LLC
|
Lanadelumab [CAS 1426055-14-2]
|
|
COVID-19-immunoregulation
|
|
HY-P99715-1mg
|
MedChemexpress LLC
|
Losatuxizumab [CAS 1801544-27-3]
|
|
Cancer-Kinase/protease
|
|
HY-P99715-10mg
|
MedChemexpress LLC
|
Losatuxizumab [CAS 1801544-27-3]
|
|
Cancer-Kinase/protease
|
|
HY-P99715-5mg
|
MedChemexpress LLC
|
Losatuxizumab [CAS 1801544-27-3]
|
|
Cancer-Kinase/protease
|
|
HY-112099-10mg
|
MedChemexpress LLC
|
Mc-Val-Cit-PAB-Cl [CAS 1639351-92-0]
|
|
Cancer-programmed cell death
|
|
HY-112099-25mg
|
MedChemexpress LLC
|
Mc-Val-Cit-PAB-Cl [CAS 1639351-92-0]
|
|
Cancer-programmed cell death
|
|
HY-112099-5mg
|
MedChemexpress LLC
|
Mc-Val-Cit-PAB-Cl [CAS 1639351-92-0]
|
|
Cancer-programmed cell death
|
|
HY-112099-50mg
|
MedChemexpress LLC
|
Mc-Val-Cit-PAB-Cl [CAS 1639351-92-0]
|
|
Cancer-programmed cell death
|
|